After FDA refusal, Takeda builds case for subcutaneous Entyvio

AbbVie’s TNF blocker Humira (adalimumab) in a head-to-head trial. ... Analysts at GlobalData have previously suggested that having two formulations of vedolizumab will allow Takeda to compete strongly against well-established ulcerative colitis drugs

Cosentyx, Entresto drive topline growth for Novartis in Q4

However, in head-to-head trials with both AbbVie’s  Humira (adalimumab) and  Skyrizi (risankizumab), Cosentyx failed to show superiority – a potential sign of trouble ahead as the psoriasis/biologic market

AbbVie creates new aesthetics division amid Allergan takeover

Ahead of the upcoming patent loss of AbbVie’s ageing blockbuster Humira, the Allergan acquisition and now the subsequent division of its aesthetics business will give AbbVie more space to focus

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

Takeda showcased a study of the intravenous formulation of Entyvio earlier this year, which positioned it head-to-head with AbbVie’s ageing immunology blockbuster Humira (adalimumab). ... In comparison, 22.5% of patients who received Humira every

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]